Pradère P, Garcia G, Humbert M, Aubier M, Taillé C
Service de pneumologie, centre de compétence pour les maladies pulmonaires rares, université Paris Diderot, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
Service de pneumologie, université Paris-Sud, hôpital de Bicêtre, AP-HP, 94270 Le Kremlin-Bicêtre, France.
Rev Mal Respir. 2016 Feb;33(2):117-27. doi: 10.1016/j.rmr.2015.07.008. Epub 2015 Sep 4.
Omalizumab, an anti-immunoglobulin E monoclonal antibody, has now been used for ten years as an add-on therapy for severe adult atopic asthma, poorly controlled by high-doses inhaled steroids and long-acting beta-agonists.
This innovative therapy has been the first biotherapy used on a large scale in severe asthma. It has shown clinical benefits, especially in the prevention of severe exacerbation, with a satisfactory safety profile. Despite its cost, it is an interesting alternative to continuous oral steroids, which cause more long-term side effects.
After ten-years of prescription of omalizumab, we review here the mechanism of action, the benefits, the main side effects, the cost-effectiveness and also the alternative indications of this interesting molecule. We also consider the practicalities of using omalizumab, particularly the importance a rigorous assessment of its efficacy after 16 weeks of treatment, and possible future therapeutic indications.
Omalizumab has proven its efficacy in large randomized studies but also in real life practice in severe allergic asthma.
奥马珠单抗是一种抗免疫球蛋白E单克隆抗体，作为高剂量吸入性糖皮质激素和长效β受体激动剂控制不佳的重度成人过敏性哮喘的附加疗法，现已使用了十年。
这种创新疗法是首个在重度哮喘中大规模使用的生物疗法。它已显示出临床益处，尤其是在预防严重发作方面，且安全性良好。尽管其成本较高，但它是持续口服糖皮质激素的一个有趣替代选择，后者会导致更多长期副作用。
在奥马珠单抗处方使用十年后，我们在此回顾该有趣分子的作用机制、益处、主要副作用、成本效益以及其他适用指征。我们还考虑了使用奥马珠单抗的实际情况，特别是治疗16周后严格评估其疗效的重要性以及未来可能的治疗指征。
奥马珠单抗已在大型随机研究以及重度过敏性哮喘的实际临床实践中证实了其疗效。
Zotero 插件